Levodopa therapy for Parkinson disease: A look backward and forward

Neurology

Volumn 86, Issue 14, 2016, Pages S3-S12

  Witt, Peter A Le ^a,b   Fahn, Stanley ^c  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT; DOPAMINE;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CATECHOLAMINE SYNTHESIS; CLINICAL FEATURE; HUMAN; MOTOR ACTIVITY; MOTOR PERFORMANCE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANIMAL; CLINICAL TRIAL (TOPIC); CORPUS STRIATUM; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PROCEDURES; TRENDS;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; CORPUS STRIATUM; DOPAMINE; DRUG DELIVERY SYSTEMS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84982156297     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002509     Document Type: Article

References (97)

1. LeWitt PA. The pharmacology of levodopa in treatment of Parkinson disease: an update. In: Calne DB, ed. Drugs for the Treatment of Parkinson's Disease: Handbook of Experimental Pharmacology, Vol 88. Berlin: Springer-Verlag; 1989:325-384.
2. LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-2476.
3. LeWitt PA. New levodopa therapeutic strategies. Parkinsonism Relat Disord 2016;22:S37-S40.
4. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 2008;23 (suppl 3):S497-S508.
5. Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 2015;30:4-18.
6. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of Parkinsonism. N Engl J Med 1967;276:374-379.
7. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
8. Hornykiewicz O. How does L-dopa work? In: Barbeau A, McDowell PH, eds. L-dopa and Parkinsonism. Philadelphia: Davis; 1970:393-399.
9. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-doparesponsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
10. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957;180:1200.
11. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959;11:490-493.
12. Guggenheim M. Dioxyphenylalanin, eine neue Aminosäure aus Vicia faba. Hoppe-Seylers Zeitschrift Physiologische Chemie 1913;88:276-284.
13. Oster KA, Sorkin SZ. The effects of intravenous injection of L-dopa upon blood pressure. Proc Soc Exp Biol Med 1942;51:67-71.
14. Holtz P, Credner K, Kroneberg G. Über das sympathikomimetische pressorische Prinzip des Hirn ("Urosympathin"). Arch Exp Path Pharmik 1947;204:228-243.
15. Wilkins RW, Judson WE. The use of rauwolfia serpentine in hypertensive patients. N Engl J Med 1953;248: 48-53.
16. Carlsson A. Monoamine-depleting drugs. Pharmacol Ther B 1975;1:393-400.
17. Carlsson A, Hillarp NA. Release of adenosine triphosphate along with adrenaline and noradrenaline following stimulation of the adrenal medulla. Acta Physiol Scand 1956;37: 235-239.
18. Carlsson A. Treatment of Parkinson's with L-DOPA: the early discovery phase, and a comment on current problems. J Neural Transm 2002;109:777-787.
19. Pardridge WM, Oldendorff WH. Kinetic analysis of blood-brain barrier transport of amino acids. Biochim Biophys Acta 1975;401:128-136.
20. Bertler A, Rosengren E. Occurrence and distribution of catechol amines in brain. Experientia 1959;15:10-11.
21. Kaufman S, Friedman S. Dopamine-b-hydroxylase. Pharmacol Rev 1965;17:71-100.
22. Espay AJ, LeWitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson disease: the case for noradrenergic enhancement. Mov Disord 2014;29:1710-1719.
23. Blaschko H. The specific action of l-dopa decarboxylase. J Physiol 1939;96:50P-51P.
24. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord 2015; 30:19-36.
25. Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase: the initial step in norepinephrine biosynthesis. J Biol Chem 1964;239:2910-2917.
26. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 2002;17: 501-508.
27. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system [in German] Klin Wochenschr 1960;38:1236-1239.
28. Hornykiewicz O. The topical localization and content of noradrenaline and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease [in German]. Wien Klin Wochenschr 1963;75:309-312.
29. Anden NE, Carlsson A, Dahlström A, Fuxe K, Hillarp NA, Larsson K. Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci 1964;3:523-530.
30. Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (5DOPA) on akinesia in Parkinsonism [in German]. Wien Klin Wochenschr 1961; 73:787-788.
31. Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K. Distribution of catechol compounds in human brain. Biochim Biophys Acta 1959;32:586-587.
32. Sano I. Biochemistry of the extrapyramidal system [in Japanese]. Shinkei Kennkyu No Shinpo 1960;5:42-48.
33. Degkwitz R, Frowein R, Kulenkampff C, Mohs U. Über die Wirkungen des L-dopa beim Menschen und deren Beinflussung durch Reserpin, Chlorpromazin, Iproniazid, und Vitamin B6. Klin Wochenschr 1960;38:120-123.
34. Barbeau A, Murphy GF, Sourkes TL. Excretion of dopamine in diseases of basal ganglia. Science 1961;133: 1706-1707.
35. McGeer PL, Boulding JE, Gibson WC, Foulkes RG. Drug-induced extrapyramidal reactions: treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine. JAMA 1961;177:665-670.
36. Friedhoff AJ, Hekimian L, Alpert M, Tobach E. Dihydorxyphenylalanine in extrapyramidal disease. JAMA 1963; 184:285-290.
37. Gerstenbrand F, Pateisky K, Prosenz P. Experiences with L-dopa in the therapy of Parkinsonism [in German]. Psychiatr Neurol 1963;146:246-261.
38. Greer M, Williams CM. Dopamine metabolism in Parkinson's disease. Neurology 1963;13:73-76.
39. Hirschmann J, Mayer K. On the control of akinesia and other extrapyramidal motor disorders with L-dopa (Ldihydroxyphenylalanine) [in German]. Deutsch Med Wochenschr 1964;89:1877-1880.
40. McGeer PL, Zeldowicz LR. Administration of dihydroxyphenylanine to Parkinsonian patients. Can Med J Assoc 1964;90:463-466.
41. Umbach W, Baumann D. Effectiveness of L-dopa in Parkinson patients with and without stereotaxic brain surgery [in German]. Arch Psychiat Nervenkr 1964;205:281-292.
42. Rinaldi F, Margherita G, Divitus E. Effects from the administration of Dopa to Parkinsonian patients pretreated with monoamine oxidase inhibitors [in Italian]. Ann Fren Scienze Affini 1965;78:105-113.
43. Bruno A, Bruno SC. Effetti della L-3,4 diidrossifenilalanina (L-Dopa) nei pazienti Parkinsoniani. Riv Sper Freniat 1966;90:39-50.
44. Fehling C. Treatment of Parkinson's syndrome with L-DOPA: a double blind study. Acta Neurol Scand 1966;42:367-372.
45. Pazzagli A, Amaducci L. Clinical experimentation of Dopa in Parkinsonian syndromes [in Italian]. Riv Neurobiol 1966;12:138-145.
46. Aebert K. What success does L-Dopa have in the treatment of Parkinsonian akinesia [in German]? Deutsch Med Wochenschr 1967;92:483-487.
47. Rinne UK, Sonninen V. A double-blind study of L-dopa treatment in Parkinson's disease. Eur Neurol 1968;1: 180-191.
48. Birkmayer W, Hornykiewicz O. Additional experimental studies on L-dopa in Parkinson's syndrome and reserpine Parkinsonism [in German]. Arch Psychiatr Nervenkr 1964;206:367-381.
49. Yahr MD, Duvoisin RC. Drug therapy of the extrapyramidal disorders. In: Vinken PJ, Bruyn GW, eds. Diseases of the Basal Ganglia. Handbook of Clinical Neurology. Amsterdam: North Holland Publishing Company; 1968:826-843.
50. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of Parkinsonism with levodopa. Arch Neurol 1969;21:343-354.
51. Cotzias GC. Manganese, melanins and the extrapyramidal system. J Neurosurg 1966;24(suppl):170-180.
52. Sacks O. Awakenings. New York: Summit Books; 1983.
53. LeWitt PA. Dopaminergic agonists in Parkinson's disease. In: Kompoliti K, Verhagen Metman L, eds. Encyclopedia of Movement Disorders, Vol 1. Oxford: Academic Press; 2010:332-336.
54. Barbeau A, McDowell FH, eds. L-Dopa and Parkinsonism. Philadelphia: Davis; 1970.
55. Birkmayer W, Hornykiewicz O. Advances in Parkinsonism. Basel: Roche; 1970.
56. BirkmayerW, Riederer P. Parkinson's Disease: Biochemistry, Clinical Pathology, and Treatment. Berlin: Springer; 1983.
57. Boshes B. Sinemet and the treatment of Parkinsonism. Ann Intern Med 1981;94:364-370.
58. Brogden RN, Speight TM, Avery GS. Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism. Drugs 1971;2: 262-400.
59. Calne DB, ed. Progress in the treatment of Parkinsonism. Adv Neurol 1973;3:1-326.
60. Hassler RG, Christ JF, eds. Parkinson-specific motor and mental disorders: roles of the pallidum: pathophysiological, biochemical, and therapeutic aspects. Adv Neurol 1984;40:1-579.
61. Lakke JPWF, Korf J, Wesseling H, eds. Parkinson's Disease: Concepts and Prospects. Amsterdam: Excerpta Medica; 1977.
62. Markham CH, Treciokos LJ, Diamond SG. Parkinson's disease and levodopa: a five year follow-up and review. West J Med 1974;121:188-206.
63. Marsden CD, Parkes JD. Success and problems of longterm levodopa therapy in Parkinson's disease. Lancet 1977;1:345-349.
64. McDowell FH, Markham CH, eds. Recent Advances in Parkinson's Disease. Philadelphia: Davis; 1971.
65. McDowell FH, Barbeau A, eds. Second Canadian-American Conference on Parkinson's Disease. Amsterdam: North Holland; 1974.
66. O'Brien CP, DiGiacomo JN, Fahn S, Schwarz GA. Mental effects of high dosage L-dopa. Arch Genl Psychiat 1971;24:61-64.
67. Poirier LJ, Sourkes TL, Bedard PJ, eds. The extrapyramidal system and its disorders. Adv Neurol 1979;24:1-529.
68. Presthus J, Holmsen R. Appraisal of long-term levodopa treatment of Parkinsonism with special reference to therapy limiting factors. Acta Neurol Scand 1974;50:774-790.
69. Rinne UK, Klinger M, Stamm G, eds. Parkinson's Disease: Current Progress, Problems, and Management. New York: Elsevier/North Holland Biomedical; 1980.
70. Rose FC, Capildeo R, eds. Research Progress in Parkinson's Disease. Tunbridge: Pitman; 1981.
71. Sandler M. Catecholamine synthesis and metabolism in man: clinical implications (with special reference to Parkinsonism). In: Blaschko H, Muscholl E, eds. Catecholamines (Handbook of Clinical Pharmacology, Vol 33). Berlin: Springer; 1972.
72. Schwarz GA, Fahn S. Newer medical treatment in Parkinsonism. Med Clin No Am 1970;54:773-785.
73. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Q J Med 1980;49: 283-293.
74. Stern GM, ed. The Clinical Uses of Levodopa. Baltimore: University Park Press; 1975.
75. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med 1975;83: 456-463.
76. Symposium on levodopa in Parkinson's disease: clinical and pharmacological aspects. Clin Pharmacol Ther 1971; 12:317-476.
77. Symposium on levodopa in Parkinson's disease. Neurology 1972;22:1-102.
78. Yahr MD, ed. The treatment of Parkinsonism: the role of DOPA decarboxylase inhibitors. Adv Neurol 1973;2: 1-303.
79. Yahr MD, ed. Current Concepts in the Treatment of Parkinsonism. New York: Raven; 1974.
80. Yahr MD. Levodopa. Ann Intern Med 1975;83: 677-682.
81. Aquino CC, Fox SH. Clinical spectrum of levodopainduced complications. Mov Disord 2015;30:80-89.
82. Anderson E, Nutt J. The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. Parkinsonism Relat Disord 2011;17: 587-592.
83. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351:2498-2508.
84. Misu Y, Goshima Y. DOPA as a neurotransmitter candidate. In: Misu Y, Goshima Y, eds. Neurobiology of DOPA as a Neurotransmitter. Boca Raton, FL: CRC Press/Taylor and Francis Press; 2006:23-34.
85. King JM, Muthian G, Mackey V, Smith M, Charlton C. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-Amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease. Life Sci 2011;89:638-643.
86. Newcomer TA, Rosenberg PA, Aizenman E. Iron-mediated oxidation of 3,4-dihydroxyphenylalanine to an excitotoxin. J Neurochem 1995;64:1742-1748.
87. Guatteo E, Yee A, McKearney J, et al. Dual effects of L-DOPA on nigral dopaminergic neurons. Exp Neurol 2013;247:582-594.
88. Nilsson D, Hansson L-E, Johansson K, Nyström C, Paalzow L, Aquilonius S-M. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998;97: 175-183.
89. LeWitt PA, Jennings D, Lyons KE, et al. Pharmacokineticpharmacodynamic crossover comparison of two levodopa extension strategies. Mov Disord 2009;24:1319-1324.
90. LeWitt PA. Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics. Mov Disord 2015;30:64-72.
91. Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease. J Clin Pharmacol 2012;52:1069-1077.
92. Verhagen Metman L, Stover N, Chen C, Cowles VE, Sweeney M. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease. Mov Disord 2015;30:1222-1228.
93. LeWitt PA, Giladi N, Gurevich T, et al. Accordion Pill carbidopa/levodopa (AP CD/LD) for treatment of advanced Parkinson's disease (PD). Mov Disord 2014;29 (suppl 1):S248.
94. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediaterelease carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12:346-356.
95. LeWitt PA, Huff FJ, Hauser R, et al. Double-blind study of an actively-transported levodopa prodrug, XP21279, in Parkinson disease. Mov Disord 2014;29:75-82.
96. LeWitt PA, Saint-Hilaire MH, Grosset DG. Inhaled levodopa (CVT-301) provides rapid improvements after administration to Parkinson's disease patients when OFF. Mov Disord 2015;30(suppl 1):S99-S100.
97. Caraco Y, Oren S, LeWitt P. Constant therapeutic levodopa (LD) plasma concentrations maintained by continuous subcutaneous (SC) administration of ND-0612, a novel formulation of LD/carbidopa (CD). Mov Disord 2013;28(suppl 1):S162.